Published in Proc Natl Acad Sci U S A on September 14, 1999
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation. Mol Biol Cell (2001) 1.53
Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol (2009) 1.40
Integrin-FAK signaling rapidly and potently promotes mitochondrial function through STAT3. Cell Commun Signal (2016) 1.38
Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology (2005) 1.23
Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. Proc Natl Acad Sci U S A (2008) 1.18
Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol Pharmacol (2008) 1.02
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer (2010) 1.01
Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol (2010) 1.00
Conditional knockout mice reveal an essential role of protein phosphatase 4 in thymocyte development and pre-T-cell receptor signaling. Mol Cell Biol (2006) 0.98
γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br J Pharmacol (2011) 0.97
Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis. APMIS (2010) 0.95
Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation. J Biol Chem (2009) 0.94
5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol Cancer Res (2010) 0.93
Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies. J Biol Chem (2012) 0.90
STATs: An Old Story, Yet Mesmerizing. Cell J (2015) 0.89
Avicin D: a protein reactive plant isoprenoid dephosphorylates Stat 3 by regulating both kinase and phosphatase activities. PLoS One (2009) 0.88
14-3-3ζ interacts with stat3 and regulates its constitutive activation in multiple myeloma cells. PLoS One (2012) 0.88
Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation. Arthritis Res (1999) 0.87
Phosphorylation of ORC2 protein dissociates origin recognition complex from chromatin and replication origins. J Biol Chem (2012) 0.86
Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase Cdelta-dependent activation of STAT3 and decreased endothelial nitric oxide synthase expression. DNA Cell Biol (2009) 0.85
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood (2016) 0.85
Deciphering STAT3 signaling in the heart: plasticity and vascular inflammation. Congest Heart Fail (2010) 0.83
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. BMC Nephrol (2016) 0.82
Modulation of PKCdelta signaling alters the shear stress-mediated increases in endothelial nitric oxide synthase transcription: role of STAT3. Am J Physiol Lung Cell Mol Physiol (2008) 0.80
Calyculin A reveals serine/threonine phosphatase protein phosphatase 1 as a regulatory nodal point in canonical signal transducer and activator of transcription 3 signaling of human microvascular endothelial cells. J Interferon Cytokine Res (2011) 0.79
Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules. J Biol Chem (2015) 0.78
Selenate enhances STAT3 transcriptional activity in endothelial cells: differential actions of selenate and selenite on LIF cytokine signaling and cell viability. J Inorg Biochem (2012) 0.77
Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells. Nat Commun (2016) 0.76
Decreased STAT3 Phosphorylation Mediates Cell Swelling in Ammonia-Treated Astrocyte Cultures. Biology (Basel) (2016) 0.75
PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Oncotarget (2016) 0.75
STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma. Int J Clin Exp Pathol (2014) 0.75
STATs and gene regulation. Science (1997) 16.55
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 15.76
Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell (1995) 10.16
Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J (1988) 8.02
Jaks and STATs: biological implications. Annu Rev Immunol (1998) 7.18
The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J (1990) 4.28
Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol Rev (1993) 3.62
Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases. J Biol Chem (1991) 3.37
STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol (1997) 3.18
Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. Science (1995) 3.10
Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science (1995) 3.07
Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res (1997) 2.24
STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem (1996) 2.10
Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J (1996) 1.85
Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci U S A (1992) 1.80
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci U S A (1996) 1.75
STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase. Proc Natl Acad Sci U S A (1995) 1.65
Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem (1992) 1.62
Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci U S A (1998) 1.56
Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene (1998) 1.48
Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A (1997) 1.47
Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia (1999) 1.45
Stat1 serine phosphorylation occurs independently of tyrosine phosphorylation and requires an activated Jak2 kinase. Mol Cell Biol (1997) 1.45
Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. EMBO J (1996) 1.40
JAK/STAT signaling by cytokine receptors. Curr Opin Immunol (1998) 1.36
STAT3 is a serine kinase target in T lymphocytes. Interleukin 2 and T cell antigen receptor signals converge upon serine 727. J Biol Chem (1997) 1.36
Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol (1992) 1.31
Interleukin-6-induced serine phosphorylation of transcription factor APRF: evidence for a role in interleukin-6 target gene induction. FEBS Lett (1995) 1.26
Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases. Toxicon (1994) 1.23
Differentiation-regulated serine phosphorylation of STAT1 promotes GAF activation in macrophages. Mol Cell Biol (1995) 1.20
Elf-1 and Stat5 bind to a critical element in a new enhancer of the human interleukin-2 receptor alpha gene. Mol Cell Biol (1996) 1.17
MHC class II molecules regulate growth in human T cells. Exp Clin Immunogenet (1994) 0.98
Signal transducer and activator of transcription-3 serine phosphorylation by insulin is mediated by a Ras/Raf/MEK-dependent pathway. Endocrinology (1997) 0.96
The role of serine/threonine phosphorylation in hematopoietic cytokine receptor signal transduction. FASEB J (1997) 0.91
Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol (1998) 0.90
Interleukin 2 induces a transient downregulation of protein phosphatase 1 and 2A activity in human T cells. Tissue Antigens (1997) 0.87
Interleukin 2 and 15 activate Stat3alpha in human T lymphocytes. Cytokine (1998) 0.81
Confidential inquiry into quality of care before admission to intensive care. BMJ (1998) 11.32
Screening for breast cancer with mammography. Cochrane Database Syst Rev (2006) 5.19
HL-A antigens and diabetes mellitus. Lancet (1974) 4.42
HL-A antigens and disease. Statistical and genetical considerations. Tissue Antigens (1974) 4.41
Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathol Microbiol Scand (1969) 4.07
HLA and disease 1982--a survey. Immunol Rev (1983) 3.87
Value of body fat mass vs anthropometric obesity indices in the assessment of metabolic risk factors. Int J Obes (Lond) (2006) 3.40
Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol (1995) 3.30
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
HL-A and disease associations--a survey. Transplant Rev (1975) 2.87
A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet (1999) 2.85
Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A (1999) 2.83
Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group. Lancet (1997) 2.70
Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum (1999) 2.66
Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet (1997) 2.54
Rapid equilibrium isopycnic CsC1 gradients. Biochim Biophys Acta (1969) 2.48
Older persons after hospitalization: a controlled study of home aide service. Am J Public Health (1972) 2.44
Use of a transposon (Tndif) to obtain suppressing and nonsuppressing insertions of the dif resolvase site of Escherichia coli. Genes Dev (1996) 2.42
Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet (1973) 2.41
Free ribosomal DNA molecules from Tetrahymena pyriformis GL are giant palindromes. J Mol Biol (1976) 2.33
Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet (1995) 2.31
A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics (1994) 2.31
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Heterotransplantation of human adenocarcinomas of the colon and rectum to the mouse mutant Nude. A study of nine consecutive transplantations. Acta Pathol Microbiol Scand A (1971) 2.25
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
Basement membrane changes in breast cancer detected by immunohistochemical staining for laminin. Cancer Res (1981) 2.21
Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol (1998) 2.11
HL-A antigens and multiple sclerosis. Lancet (1972) 2.09
Nonsense suppressors of Saccharomyces cerevisiae can be generated by mutation of the tyrosine tRNA anticodon. Nature (1976) 2.07
Brain glutamate transporter proteins form homomultimers. J Biol Chem (1996) 2.01
Interference filters for improved immunofluorescence microscopy. Acta Pathol Microbiol Scand (1969) 1.97
MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. Transplant Rev (1975) 1.97
Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet (1997) 1.92
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27. Arthritis Rheum (1982) 1.83
Growth and antigenic properties of a biopsy-derived Burkitt's lymphoma in thymus-less (nude) mice. Int J Cancer (1973) 1.80
Somatic APC mosaicism: an underestimated cause of polyposis coli. Gut (2007) 1.79
HLA genotype distribution and genetic models of insulin-dependent diabetes mellitus. Ann Hum Genet (1981) 1.78
Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. APMIS (1999) 1.77
Genetics of HLA disease association. Annu Rev Genet (1981) 1.74
Evidence for accelerated colorectal adenoma--carcinoma progression in MUTYH-associated polyposis? Gut (2011) 1.74
Interaction of convulsive ligands with benzodiazepine receptors. Science (1982) 1.72
The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene (2001) 1.72
Human cell-mediated cytotoxicity against modified target cells is restricted by HLA. Nature (1977) 1.69
Prediction of protein secondary structure at 80% accuracy. Proteins (2000) 1.65
ABC of intensive care. Criteria for admission. BMJ (1999) 1.65
Studies of the HLA system and insulin-dependent diabetes mellitus. Diabetes Care (1980) 1.63
Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet (1998) 1.62
Task-dependent influences of attention on the activation of human primary visual cortex. Proc Natl Acad Sci U S A (1998) 1.60
Nomenclature for factors of the HLA system, 2004. Tissue Antigens (2005) 1.57
CD3 gamma contains a phosphoserine-dependent di-leucine motif involved in down-regulation of the T cell receptor. EMBO J (1994) 1.54
SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tissue Antigens (2004) 1.52
Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP). J Biol Chem (1999) 1.51
CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol (1998) 1.50
Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet (1994) 1.50
Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene (1996) 1.48
Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A (1997) 1.47
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens (2004) 1.47
Metastases to the breast from extramammary carcinomas. Acta Pathol Microbiol Scand A (1981) 1.45
The HL-A7 histocompatibility antigen in sarcoidosis in relation to tuberculin sensitivity. Tissue Antigens (1975) 1.45
Perceptions and acceptability of the female condom [Femidom] amongst commercial sex workers in the Songkla province, Thailand. Int J STD AIDS (1998) 1.45
Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia (1999) 1.45
In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod (2010) 1.45
In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia (2004) 1.44
Flash pulmonary oedema. Lancet (2001) 1.43
HLA-D and -DR antigens in genetic analysis of insulin dependent diabetes mellitus. Diabetologia (1981) 1.43
Regulation and function of the CD3gamma DxxxLL motif: a binding site for adaptor protein-1 and adaptor protein-2 in vitro. J Cell Biol (1997) 1.42
Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. Clin Genet (2011) 1.42
Identification, paracrine generation, and possible function of human breast carcinoma myofibroblasts in culture. In Vitro Cell Dev Biol (1992) 1.41
Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences. Scand J Immunol (1988) 1.40
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia (2001) 1.40
Nomenclature for factors of the HLA system, 1998. Tissue Antigens (1999) 1.40
Determination of characteristics of interference filters. Ann N Y Acad Sci (1971) 1.39
[Transplantation. Blood, bone marrow and solid organs]. Ugeskr Laeger (2000) 1.39
Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology (2001) 1.39
Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci U S A (1998) 1.38
Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet (2005) 1.38
The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum (2000) 1.37
Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol (1988) 1.37
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family. Glycobiology (1999) 1.37
HLA--Dw4 and rheumatoid arthritis. Tissue Antigens (1979) 1.36
Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogenet (1992) 1.35
Scandiatransplant: preliminary report of a kidney exchange program. Transplant Proc (1971) 1.32
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia (2013) 1.31
Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia (2005) 1.31